Page 6 - Onxeo Stock Exchange News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Onxeo stock exchange. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Onxeo Stock Exchange Today - Breaking & Trending Today

Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer

07.04.2022 - Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA . Seite 1 ....

Epizyme Inc , Chief Medical , Development Officer ,

Onxeo Reports its Full-Year 2021 Financial Results and Announces Additional Financing of €12 Million

> Cash position of €17.9 million as of December 31, 2021 > Additional financing of €12 million subscribed by historical shareholders Invus and Financière de la Montagne in the form of the issuance ....

United States , France General , Julien Miara , Acrotech Biopharma , Judith Greciet , Emmanuel Huynh , Arthur Rouill , Onxeo Sa Euronext , Robertl Coleman , Valerie Leroy , Gustave Roussy , Bryan Giraudo , Institut Curie , Gossamer Bio Inc , Audit Committee , Trademark Office , American Association For Cancer Research , Scientific Advisory Committee , Company Group , Us Oncology Network , Euronext Growth Paris , Nasdaq First North Copenhagen , Guaranteed Loans , Revocan Phase , American Association , Cancer Research ,

Onxeo to Present New Preclinical Data Highlighting AsiDNA's Ability to Fight Tumor Resistance and Protect From Anticancer Treatment Toxicity at AACR Annual Meeting 2022

AsiDNA proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA proven to protect healthy cells when combined with conventional antitumor treatments Regulatory ....

United States , France General , Wael Jdey , Nicolas Merigeau , Onxeo Sa Euronext , Valerie Leroy , Emmanuel Huynh , Marie Dutreix Institut Curie , American Association For Cancer Research Annual Meeting , Gilles Favre Cancer Research Center , Company Group , Euronext Growth Paris , First North Copenhagen , American Association , Cancer Research Annual Meeting , Gilles Favre , Cancer Research Center , Marie Dutreix , Institut Curie , Preclinical Lead , Disease Biology , Drug Resistance Mechanisms , Daylight Time , Euronext Paris , Nasdaq First North ,

Onxeo S.A.: Onxeo's New Preclinical Data Confirm the Relevance of Combining AsiDNA With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors

These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022 Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), ("Onxeo" or ....

France General , Wael Jdey , Nicolas Merigeau , Onxeo Sa Euronext , Valerie Leroy , Emmanuel Huynh , Anticancer Therapies Congress , Company Group , Euronext Growth Paris , First North Copenhagen , Preclinical Lead , Euronext Paris , Nasdaq First North ,

Onxeo S.A.: Onxeo Announces its Financial Agenda for 2022

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative ....

France General , Brigitte Le Guennec , Nicolas Merigeau , Onxeo Sa Euronext , Emmanuel Huynh , Brian Ritchie , Regulatory News , Euronext Growth Paris , First North Copenhagen , Euronext Paris , Inhibitor Administered Intravenously , Sci Advisors , North Kapital Partner ,